INTRODUCTION
============

Temporal and spatial regulation of gene expression results from the interaction of transcription factors (TFs) with specific *cis*-regulatory DNA sequences. These regulatory sequences are typically organized in a modular fashion with each module containing one or more binding sites for a specific combination of TFs ([@gkr621-B1]). A '*cis*-regulatory module' (CRM) can thus be defined as a collection of TF-binding sites that function jointly to regulate a discrete aspect of a gene\'s expression pattern. CRMs are generally described as being short (\<1000 bp) contiguous stretches of DNA, located few to hundreds of kilobases away from their associated gene, and are found five-prime, three-prime and within introns of the gene. Davidson ([@gkr621-B2]) estimates that there may be as many as 10-fold more CRMs than genes, yet the vast majority of CRMs have not been identified. The problem of CRM discovery is complicated by the fact that unlike protein-coding regions, which have recognizable sequence features such as open reading frames and codon-usage biases, no similar properties are known for CRMs; and unlike promoters, which by definition lie immediately five-prime to the gene and which contain a limited number of well-defined sequence motifs ([@gkr621-B3]), CRMs are constrained neither in location nor by motif composition.

The traditional approach to CRM identification involves a tedious process of testing many sequence fragments for regulatory activity in a reporter gene assay. Recently developed genomic techniques have led to relatively rapid screens for potential gene-regulatory regions; such techniques include chromatin immunoprecipitation coupled to genomic tiling arrays (ChIP-chip) ([@gkr621-B4]) and ultra high-throughput sequencing (ChIP-Seq) ([@gkr621-B5]). Despite their great promise, these empirical methods have limitations: it is currently infeasible to assay all tissue types under all conditions, and potential CRMs may be missed by these techniques. In recent years, computational methods have provided an attractive alternative for module identification. Computational methods ([@gkr621-B6; @gkr621-B7; @gkr621-B8; @gkr621-B9; @gkr621-B10; @gkr621-B11]) typically start with a small set of relevant TFs and their binding motifs, and search the genome for clusters of putative binding sites (motif matches). However, this approach is ineffective if the relevant TFs and/or their binding specificities are unknown. Motif databases for *Drosophila* currently catalog only a fraction of the estimated number of TFs ([@gkr621-B12; @gkr621-B13; @gkr621-B14]). Intense efforts are being made to characterize TF-binding specificities in mouse and fly ([@gkr621-B15],[@gkr621-B16]), but these efforts are labor intensive and expensive, and the problem of sparse motif knowledge may thus persist for scientists studying organisms other than human, mouse and fruit fly. Moreover, for the majority of regulatory systems, some or most of the relevant TFs have not yet been identified. For these reasons, the application of motif-based computational methods has been limited to a few well-understood biological systems, where the necessary prior knowledge is available. Specialized computational tools to discover motifs from the training data may alleviate the problem, but the modest success rate of motif finding programs (especially for metazoan genomes), as suggested by past surveys ([@gkr621-B17; @gkr621-B18; @gkr621-B19]), casts doubts upon the prospect of CRM discovery based on computational motif finding.

This article examines CRM prediction in the common scenario where knowledge of the relevant TFs and/or their binding specificities (motifs) is missing. In particular, we ask the following question: suppose a small set of modules participating in a transcriptional network is known *a priori*. Can we use such information as 'training data' to guide the search for other modules in that network? We call this task the 'supervised CRM prediction problem'. The success of a CRM prediction may be defined as the ability of the predicted sequence to drive a discrete temporal and/or spatial expression pattern. An additional, stricter criterion for success is that the predicted CRM recapitulates the common expression pattern of the training CRMs.

Here, we undertake supervised CRM discovery without assuming motif knowledge or the ability to accurately discover the relevant motifs *ab initio*. In a previous publication ([@gkr621-B20]), we proposed various statistics to capture the sequence similarity (due to shared TF-binding sites) between a candidate CRM and the training set of modules. Our study included previously reported approaches to the problem ([@gkr621-B21],[@gkr621-B22]) as well as some new statistical techniques. We demonstrated that these techniques could then be used effectively to discover CRMs in *Drosophila* and human genomes. Narlikar and colleagues ([@gkr621-B23]) used a similar approach to predict human heart enhancers. Here, we advance the state-of-the-art in solving this problem by developing a new statistical approach that improves significantly upon previous methods. This new score is based on 'interpolated Markov models' (IMM) and the use of multi-species comparison. An IMM can be thought of as a combination of Markov chains of varying orders, and considers the frequencies of words of variable length in learning a generative probabilistic model from the training CRMs. We train an IMM on the training set of CRMs from *D. melanogaster* as well as their orthologs from other *Drosophila* species, and use the likelihood ratio of this model and a suitable null model as the score of a candidate CRM. The new method is shown to be superior to existing techniques in terms of predictive accuracy, which is assessed using a new statistical test that extends the widely used Hypergeometric test to correct for an important bias present in this test as applied to our setting.

We experimentally validated 12 new CRM predictions by examining their regulatory activity *in vivo*, and found 10 of these to be functional*.* Moreover, we observed that the new IMM score can effectively discriminate CRMs whose regulatory activity matches that of the training set from sequences that either do not drive expression or drive an expression pattern different from that of the training set.

The new CRM prediction method and evaluation strategy developed here are made publicly available at <http://veda.cs.uiuc.edu/scrm-2/>. The method can also be applied on the *Drosophila* genome through an online genome browser interface (<http://veda.cs.uiuc.edu/gs>, plugin 'Supervised CRM Discovery').

MATERIALS AND METHODS
=====================

Data sets
---------

The CRM training sets were obtained from ([@gkr621-B24]). The corresponding expression gene sets were taken from [Supplementary Table S10](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1) in ([@gkr621-B20]) (see Methods in [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1) for more details). Both training sets and expression gene sets are publically available at: <http://veda.cs.uiuc.edu/scrm-2/>.

IMM-based score
---------------

We implemented the IMM introduced by ([@gkr621-B25]) for finding microbial genes. Let *S* = {*s*~1~, *s*~2~,..., *s*~N~} be a sequence of length *N*. For an *n*th-order IMM, the conditional probability of generating *s~i~* given its preceding context (of *n* characters), is: Here, is proportional to the frequency of the word in training data and is a 'mixture weight' that depends on the number of occurrences of the word in the training data \[; see ([@gkr621-B25]) for details\]. Thus, is modeled as a mixture over *n* different probability distributions on , each of which is conditioned on a context of a different length (0, 1,..., *n*).

We score every candidate CRM S using the log likelihood score defined as: where and are two 5th-order IMMs trained on positive and negative sequences, respectively. The training set was used as positive sequences (both strands were used for training the model while ignoring the statistical dependencies between the strands), while the negative sequences used were regions of non-coding genomic sequence with G/C content similar to the native flanks of the CRMs. The training data set is publicly available at: <http://veda.cs.uiuc.edu/scrm-2/>

Multi-species scoring scheme
----------------------------

Given a training set of CRMs from *D. melanogaster*, we obtained orthologous sequences of each CRM from 10 other *Drosophila* species using the lift Over program from the UCSC Genome Browser database, and treated the resulting set of CRMs as the sequence data on which the model (IMM or HexMCD) was trained (see Methods in [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1)). Fewer than 4% of the CRMs were missing an ortholog in one or more species, which eliminates any potential bias toward CRMs for which more species are alignable.

Locus length-aware Hypergeometric test
--------------------------------------

A significance test of overlap between two gene sets is traditionally performed with the Hypergeometric test. However, this test assumes that every gene is equally likely to be selected *a priori*. This assumption is not true for the 'predicted gene set' in our setting, which is the set of genes nearest to predicted CRMs, since gene loci vary in length across the genome ([@gkr621-B26]). We confirmed that such variation in locus lengths is true for our data sets ([Supplementary Figure S1A](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1)). We designed the 'locus length-aware Hypergeometric test' (LLHT) to correct for this bias. Our key idea is to assign to each gene a prior probability of being sampled, in proportion to its locus length. Other than this modification, the LLHT calculations are identical to the Hypergeometric test. We compared evaluation *P*-values obtained using LLHT with those based on the Hypergeometric test, and found the former to be noticeably more conservative for most of the 33 data sets ([Supplementary Figure S1B](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1)). We also undertook a simulation-based experiment to assess the specificity of the two tests, and found that the Hypergeometric test is highly susceptible to false positives when the gene set has atypical locus lengths, while the LLHT retains its high specificity in this scenario ([Supplementary Table S1](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1)).

*Drosophila* reporter constructs and transgenic analysis
--------------------------------------------------------

Genomic sequences were generated by PCR and confirmed by sequencing; genome coordinates for predicted and tested CRMs are provided in [Supplementary Table S2](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1). The putative CRM sequences were subcloned into plasmid pattBnucGFPs, a ϕC31-enabled *Drosophila* transformation vector containing EGFP under the control of a minimal hsp70 promoter (details available on request). Transgenic flies were produced by Genetic Services Inc. (Cambridge, MA, USA) by injection into line attP2. Homozygous transgenic embryos were collected, fixed and stained with antibodies to GFP (Abcam, ab290) using standard methods. Muscle expression was visualized using anti-Tropomyosin (Babraham, MAC 141). DIC microscopy was performed using a Zeiss Axioplan microscope with a Retiga-EXi camera (Qimaging) and Openlab software (Improvision). Fluorescent images were acquired using a Leica SP2 confocal microscope. All images were color corrected and contrast adjusted in Adobe Photoshop.

RESULTS AND DISCUSSION
======================

The problem
-----------

Suppose we are given a set *T* of CRMs (called the 'training set') that are known to drive similar expression patterns. For example, these could be CRMs that regulate genes with early mesodermal expression or genes that are involved in wing development. The task is to search the genome for other CRMs that drive an expression pattern similar to those in the training set *T.* A successful method to perform this task will capture the *cis*-regulatory signatures of TFs regulating *T*, and search genome wide for occurrences of those signatures. A predicted CRM can be validated by testing its function in a reporter gene assay and judging if its expression pattern is similar to that of the training set. We refer to the task just defined as the 'supervised CRM prediction' problem. Note that the problem is not completely specified in this formulation, since we do not precisely lay down what 'similarity of expression pattern' means. Instead, we allow the domain specialist to determine which characteristics of an expression pattern are used to define *T* and to judge the success of a prediction. One simple way to define *T* (in *Drosophila*) is to search the REDfly CRM database ([@gkr621-B27]) with specific expression terms, such as 'mesoderm' or 'wing', thereby retrieving CRMs that have been shown to drive expression in the mesoderm or wing of the fly, respectively.

It is possible that a predicted CRM upon experimental testing shows regulatory activity in agreement with a neighboring gene\'s expression pattern, but this regulatory activity does not match that of the training set *T*. This is possible if TFs regulating the training set pleiotropically participate in a different regulatory network; the CRM prediction method may correctly learn the *cis*-regulatory signatures of such TFs and correctly identify a CRM that has those signatures, but the CRM may belong to the second network and hence show activity that does not match the training set. In cognizance of the above possibility, we define a second alternative criterion for a successful prediction: a CRM that drives an expression pattern matching that of a neighboring gene. In our experimental evaluations, we will examine success rates for prediction using both criteria introduced here.

A new scoring scheme for supervised CRM prediction
--------------------------------------------------

An obvious approach to supervised CRM prediction is to scan the genomic sequence with a shifting window of fixed size, and score the window for similarity to the training set of CRMs. The crucial aspect of this approach is the scoring system for matching a candidate module ('test CRM') to the training set. Different scoring systems have been proposed in the past, as reviewed and evaluated in our previous work ([@gkr621-B20]). All of these scores have been based on comparing the frequencies of short words (henceforth called 'k-mers') between the test CRM and the training set. This is a reasonable strategy, since the regulatory function of CRMs is believed to be encoded in the types and numbers of transcription factor-binding sites. Specifically, binding sites that occur repeatedly in the training CRMs ought to cause some level of overrepresentation of specific k-mers, and the occurrence of such words in the test CRM should then indicate functional similarity. The kinds of scores that have been explored in this context include Markov chain-based scores ([@gkr621-B22]), dot product-based scores ([@gkr621-B28]), scores based on Poisson statistics ([@gkr621-B29]) and others ([@gkr621-B30],[@gkr621-B31]). For statistical convenience, these scores have been based on frequencies of k-mers of a fixed length (chosen from the range 5 to 8). However, in reality, the recognition motifs of different TFs are of varying lengths and binding sites of the same TF are known to display some amount of variability in sequence. For these reasons, the use of fixed length k-mers in the statistical scores may be problematic. While longer k-mers might reflect the binding site pattern more accurately, they may not have the statistical support necessary for robust testing, due to the variability among sites. Moreover, a CRM comprises binding sites of different TFs, with varying lengths, further undermining the use of fixed length k-mers in capturing the overall binding site composition of the training set. One natural solution to this problem is to start building a model (of the training set) with the shortest k-mers and attempt to include longer words whenever there are 'enough' occurrences of the word in the training data. This is the key idea in the statistical model we adopt here: a *k*th order IMM ([@gkr621-B25]), which is a mixture of Markov models of all orders up to order k. As in a fixed order Markov chain, the IMM computes the probability of generating a sequence by multiplying the probabilities of each character (nucleotide) given the characters before it. However, instead of conditioning on a fixed number (say, *k*) of previous characters, the probability is calculated separately by looking at 1, 2,... *k* previous characters, and a linear combination of these probabilities is the multiplicative factor contributed by the current character (See Materials and methods section).

We train two 5^th^ order IMMs, one on the training set ('positive' model) and one on suitably chosen non-CRM or 'background' sequences ('negative' model), and score every candidate sequence by calculating the (log)-likelihood ratio between two models. A positive score means that the candidate sequence is more likely to have been generated by (i.e. is more similar to) the positive model. This score is henceforth called the IMM score.

Exploiting multi-species sequence data
--------------------------------------

Functional binding sites are known to be under evolutionary constraints, a fact that can be used to guide the search for potential CRMs ([@gkr621-B32]). As a simple implementation of this idea, we trained the IMM using training CRMs from *D. melanogaster* as well as their orthologs from 10 other *Drosophila* genomes. The log-likelihood ratio score derived from the model(s) trained in this manner is henceforth called the multi-species IMM (msIMM) score. Note that this approach does not use alignment information except when determining the boundaries of the orthologs of a training CRM. That is, it does not rely upon alignments of orthologous CRMs, and thus it is free from artifacts of potential errors in such alignments. Evolutionary comparison in this manner also provides a natural way to 'smooth' the counts of k-mers, as explained next. Binding sites are known to be variable, yet standard Markov chains as well as the IMM use counts of exact matches to a k-mer to quantify the importance of that k-mer in the generative model. Previous methods have attempted to address this issue by allowing for a small number (e.g. 1) of mismatches to the word in counting its occurrence---a strategy that is rather simplistic in its modeling of binding site variability. Examining many orthologs of a CRM provides a natural way to capture the variability of binding sites, to be used in training a model.

Evaluation methodology
----------------------

Given a set of CRM predictions genome wide, the definitive test of their accuracy would be to determine experimentally if each CRM drives an expression pattern in the expected tissue and/or developmental stage. Since such tests are typically not performed *en masse* (due to resource limitations), we need an *in silico* evaluation strategy. In our previous work, we proposed the following strategy, which exploits existing databases of expression pattern annotation across thousands of genes in *D. melanogaster* ([@gkr621-B33]) \[BDGP (<http://www.fruitfly.org>)\]. It is possible to obtain, for any given training set *T*, a corresponding set *G~E~* of genes with expression patterns similar to those of *T*. Successful CRM prediction (by both criteria described in 'Introduction' section) implies that CRMs predicted using the training set *T* regulate genes with similar expression patterns, i.e. the predictions would be overrepresented in the control regions of genes in *G*~E~. In other words, if we consider the CRM predictions for the training set *T*, and denote the set of 'corresponding' genes (e.g. closest neighbors) as *G*~T~, we could use the statistical significance of the overlap between *G*~T~ (the 'predicted gene set') and *G*~E~ (the 'expression gene set') as an assessment of prediction accuracy ([Figure 1](#gkr621-F1){ref-type="fig"}A). This approach to evaluating CRM prediction has been used by several groups previously ([@gkr621-B20],[@gkr621-B22],[@gkr621-B32],[@gkr621-B34]) and is a natural option to adopt when the existing knowledge of functional CRMs in a regulatory network is sparse, yet gene expression databases are available (see Methods in [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1), Notes 1 and 2 for more details). We evaluated the msIMM score in this manner, using the LLHT for statistical assessment of enrichment. This is a generalization of the widely used Hypergeometric test, which we designed specifically for assessing the significance of overlap between two gene sets (see 'Materials and Methods' section; Materials in the [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1)). We used 33 training sets and their corresponding expression gene sets, collectively called 'data sets', from ([@gkr621-B20]), based on the REDfly ([@gkr621-B35]), FlyBase ([@gkr621-B33]) and BDGP ([@gkr621-B36]) databases (see 'Materials and Methods' section). [Figure 1](#gkr621-F1){ref-type="fig"} describes the complete pipeline of supervised CRM prediction by the IMM score and the evaluation strategy. Figure 1.**(A)** General scheme for evaluation of a CRM discovery method. We first select a set of genes from BDGP (or FlyBase) with expression patterns commensurate with those of the CRMs in a data set. We next take the modules predicted for that data set and extract their nearest neighboring genes ('predicted gene set'). (In this step, we ignore predicted modules that overlap with any training CRMs.) Finally, we perform a Hypergeometric test of enrichment between the expression gene set and the predicted gene set. (**B**) IMM of order *n* is a mixture of Markov models up to order *n*. '0th MM', '1th MM',..., '*n*th MM' denote Markov models of order 0, 1, ... , *n*, respectively. are the mixture weights. (**C**) Scorer scores every windows of length 500 bp with 50 bp shift across the entire genome. In this toy example, the score of each sliding window (orange lines) is shown as blue bar.

Evaluation results
------------------

The methods evaluated included the single and multi-species versions of the IMM score, the three best performing methods from ([@gkr621-B20])---HexMCD \[derived from ([@gkr621-B22])\], PAC-rc \[derived from ([@gkr621-B29])\] and HexYMF-s200-rc, as well as a motif-based approach called Clover-ClusterBuster ([@gkr621-B20])---that uses 'Clover' ([@gkr621-B37]) for motif selection and 'ClusterBuster' ([@gkr621-B8]) for scanning with selected motifs (see Methods in [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1) for more details)---and a newer alignment-free method from ([@gkr621-B38]) (henceforth called AJTO). We also implemented a multi-species version of HexMCD (called msHexMCD), as we had done for the IMM score. The comparison between IMM and HexMCD is of special interest as both are based on a Markov chain formulation, but HexMCD uses a fixed order (of 5), in contrast to the interpolated order approach of IMM. We obtained the 'predicted gene set' (*G*~T~, of size 200) computed a *P*-value (LLHT based) for each method---data set pair, henceforth called the 'evaluation *P-*value'. We then counted how many data sets (out of 33 in our test-bed) yielded an evaluation *P-*value better than a threshold, and varied this threshold. The results are shown in [Figure 2](#gkr621-F2){ref-type="fig"}A. The msIMM score was found to be superior to all other methods by this criterion. For example, msIMM had an evaluation *P-*value better than E-5 on eight data sets, compared to the second best (non-IMM) method msHexMCD for which the corresponding number was five data sets. At E-10, the corresponding numbers were four data sets for msIMM, one for msHexMCD and IMM and zero for all other methods.The msIMM score yields clearly better results than the single species IMM score, indicating the advantage of using multi-species data in the training phase. This trend was also seen when comparing the multi-species version of HexMCD to the corresponding single-species score used in ([@gkr621-B20]).The single species IMM score was found to be superior to the single species HexMCD score and to the other single species scores (PAC-rc, HexYMF-s200-rc), revealing the advantage of using variable length words to model CRMs. Figure 2.Evaluation of methods. For each method, shown is (**A**) the number of data sets for which the evaluation *P-*value is significant at different LLHT *P-*value thresholds. For clarity, all single species methods are formatted as dashed lines and the two multi-species methods are shown as solid line. (**B**) *Y*-axis shows the number of overlaps between the expression gene set and the top k predicted genes for 'imaginal_disc.2' data set. (See [Supplementary Figure S2A](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1) and [S2B](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1) for all other data sets.).

The AJTO method led to no data sets with evaluation *P*-value \< 0.001. Since we have relatively little experience as users of this software ([@gkr621-B38]), we chose to exclude it from further comparisons, to avoid making any biased inferences about its accuracy.

To provide a more detailed view of the above comparisons, we plotted the overlap between the expression gene set and the top *k* predicted genes, as a function of *k* ([Figure 2](#gkr621-F2){ref-type="fig"}B; [Supplementary Figure S2A](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1) and [S2B](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1)), for one particular data set (complete results in [Supplementary Figure S2A](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1)). While most methods are comparable to each other in the high specificity range (e.g. ≤75 predictions), the msIMM method distinguishes itself from the others in the top 100--200 predictions. (Note that the set *G*~T~ is of size 200 for each method, for fair comparison above.) We note, however, that this particular pattern of improved performance is not common to all data sets ([Supplementary Figure S2A](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1)).

We also compared the evaluation *P-*value of msIMM to the *P-*value of the best method reported in ([@gkr621-B20]), for all 15 data sets where this evaluation was performed in ([@gkr621-B20]). These are listed in [Table 1](#gkr621-T1){ref-type="table"}. (See [Supplementary Table S3](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1) for evaluation *P-*value of all methods in all data sets.) In every data set, the msIMM *P-*value is better than or similar to that of the competing method, with the most dramatic improvements observed in the data sets 'cns.1' (E-5 to E-9), 'imaginal_disc.1' (E-6 to E-11) and 'ventral_ectoderm.1' (E-4 to E-12). Table 1.Comparison between evaluation *P-*values of msIMM and the best method from ([@gkr621-B20]), for the 15 data sets that were reported on by ([@gkr621-B20])![](gkr621t1.jpg)[^1]

In the above presentation, a method\'s performance is assessed based on the overlap between the predicted gene set (200 genes with the strongest predicted CRMs in their control regions) and the expression gene set (see Methods in [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1), Note 1). We also examined the entire distribution of a method\'s score for each gene in the expression gene set and compared it to the score distribution from a random collection of genomic segments (with lengths matching the gene control regions). These two distributions were compared using a Wilcoxon rank sum test, and the resulting *P-*value indicates how well the particular score discriminates the expression gene set (which should have CRMs) from the randomly chosen segments (which should only have coincidental occurrences of CRMs). The *P-*values are shown for each data set and each method in [Table 2](#gkr621-T2){ref-type="table"}. It is clear from this evaluation that the msIMM score is best able to discriminate between the expression gene set and the random set, for the most number of data sets. Table 2.Discrimination between control regions of an expression gene set and random sequences of matching lengths![](gkr621t2.jpg)[^2]

Experimental validation
-----------------------

We chose 12 putative CRMs predicted using the 'mesoderm' and 'somatic muscle' training sets (six for each), and tested them for regulatory activity *in vivo*. These two data sets were chosen partly because their evaluation *P-*values were significant but not among the best. (This is especially true for the 'somatic muscle' set; evaluation *P* = 0.03.) Unlike ([@gkr621-B20]), where the tested CRMs were from the data set with the strongest evaluation *P-*value ('blastoderm', *P =* 5E-13), our goal here was to investigate the effectiveness of our methods in what seem to be more challenging data sets. We also note that these two data sets are not exclusive from other data sets (e.g. 'visceral mesoderm') in terms of their defining expression patterns, which creates additional difficulties for supervised CRM discovery. The 12 candidate CRMs were selected by the following criteria: they are located near genes in the respective expression gene set;they collectively fall across the spectrum of msIMM scores, allowing us to examine (through direct experimental assays) the accuracy of this new scoring scheme not just at its highest scoring predictions but also at the medium and low scoring predictions; andeach candidate scores well by either msIMM or PAC-rc, i.e. a candidate with a relatively low msIMM score (\<0) has some supporting evidence in favor of it being a potential CRM.

[Figure 3](#gkr621-F3){ref-type="fig"} summarizes the results of our experiments. Of the 12 tested sequences, 10 (83%) were found to drive reporter gene expression in a tissue- or stage-specific pattern (see Methods in [Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1), Note 3). The two failed predictions (corresponding to genes *tkv* and *tsh*) were the two lowest scoring predictions of msIMM (in this set). We then examined the two specific success criteria we laid down in the beginning ('Introduction' section). Due to the non-exclusive and overlapping nature of the expression patterns found within each of the two training sets, we considered any mesodermal gene expression as matching the training pattern. Of the 12 tested sequences (50%), 6 showed reporter gene expression in one or more mesodermal tissues ([Figure 3](#gkr621-F3){ref-type="fig"}A--L). Remarkably, the msIMM score was able to predict success by this criterion with 90% accuracy. In particular, a threshold value of the msIMM score was able to separate the pattern-specific CRMs from the non-specific CRMs (or non-CRMs) with only one false positive error ([Figure 3](#gkr621-F3){ref-type="fig"}U). Of the 12 predicted CRMs, 10 (83%) drive an expression pattern matching at least in part that of the endogenous expression of the nearest gene. Figure 3.*In vivo* validation of 12 Drosophila CRM predictions. Transgenic embryos were stained with antibodies to GFP to detect reporter gene expression. Embryos are oriented anterior to the left. Panels A, F, G, K, M, O and S are dorsal views; H and N are ventral views; the remainder are lateral views with dorsal to the top. 'Pattern-specific' CRMs are shown in panels A--L and non-pattern specific CRMs in panels M--T. (**A**) The *Antp_161* CRM drives expression in several tissues, including the visceral mesoderm (arrowhead) and the non-mesodermal midgut (asterisk). The endogenous *Antp* gene is expressed in a much more restricted manner, suggesting that the reporter gene expression is either ectopic or that the CRM is associated with a different gene of undetermined identity. (**B**) Co-labeling for Tropomyosin (magenta) shows GFP expression (green) in somatic muscles, in particular the lateral transverse muscle fibers (arrowheads). (**C** and **D**) The *how_171* CRM drives expression in the mesoderm in both mid-stage (C) and late-stage (D) embryos, consistent with *how* gene expression. (**E--H**) The *noc_532* CRM is active in many *noc*-positive tissues throughout embryogenesis. Pictured is metameric expression in both ectoderm and mesoderm at stage 9 (E), in the visceral mesoderm (F, arrowhead), in the mesodermally-derived lymph glands (G, arrowhead), the ventral nerve cord (H, arrow) and the hindgut (H, arrowhead). (**I**) *Mhc_537* regulates reporter gene expression (green) in a subset of *Mhc*-positive mesodermal cells including longitudinal visceral muscles (arrow) and several ventral oblique somatic muscle fibers (arrowheads). (**J**) Longitudinal visceral muscle precursors express GFP under the control of the *slou_847* CRM (arrowheads), cells not positive for endogenous *slou* expression. Expression is also observed in the supraesophogeal ganglion (**K**) and ventral nerve cord (data not shown), consistent with known *slou* expression patterns. Inset shows a more dorsal view of the anterior portion of the embryo in the main panel. (**L**) *mbc_64* drives expression in the *mbc*-positive mesoderm, pictured here at stage 16. (**M** and **N**). Expression driven by the *lola_648* CRM is confined to the central nervous system in both mid-stage (M) and late-stage (N) embryos, consistent with *lola* expression. *lola_648* overlaps the independently discovered CRM40 of ([@gkr621-B40]). (**O**) The *slou-828* CRM regulates reporter gene expression in tissues that are not *slou-*positive including cells in the antenno-maxillary complex (black arrow), the posterior spiracles (arrowhead) and cells in the anterior and posterior portions of the foregut (white arrow and data not shown). (**P**) *slou_828*-controlled expression is also observed in the midgut, consistent with normal *slou* expression. (**Q** and **R**) The *rib_120* CRM drives expression throughout hindgut development, part of the normal *rib* expression pattern. (**S** and **T**) Reporter gene expression regulated by the *ama_299* CRM is restricted to the central nervous system. Although *ama* is not expressed in the CNS of late-stage embryos ([@gkr621-B41]), earlier expression in the ventral midline beginning at stage 8 (data not shown) is consistent with *ama* expression at that stage. (**U**) Summary of results and msIMM scores for each predicted CRM. Names are based on the closest gene to each predicted module and do not necessarily reflect the actual gene regulated by the CRM. 'Data set' indicates the data set from which the CRM was predicted ('S' and 'M' for *somatic muscle* and *mesoderm* respectively). 'Pattern?' indicates whether the tested sequence drives a spatial and/or temporal expression pattern. 'Matches training set?' and 'Matches gene?' indicate whether the expression pattern agrees with that of the training set or the nearest gene, respectively. Check marks/blue coloring denote a positive result, crosses and yellow coloring a negative result. Mixed blue and yellow coloring is used for cases where both endogenous and ectopic gene expression patterns are observed. 'Score' shows msIMM scores for each tested CRM. The gray arrow points to the best decision stump on msIMM scores in terms of predicting pattern-specific CRMs.

Visualization tool
------------------

In addition to making the source code directly available for download, we have developed a plugin for Gbrowse ([@gkr621-B39]), called 'Supervised CRM discovery', through which the user can select a set of related CRMs as their starting point and browse a genomic region of interest for other putative CRMs with similar functionality. The plugin can be accessed via: <http://veda.cs.uiuc.edu/gs>.

CONCLUSION
==========

We have presented a new statistical method for genome-wide prediction of CRMs, beginning with a collection of known modules in the regulatory network of interest. This problem of 'supervised CRM prediction' was visited in our previous work ([@gkr621-B20]), where we established the necessary benchmarks and evaluation methodology, and also compiled a suite of pre-existing and novel methods to solve the problem. The new method we propose now is shown to be superior to the best of the methods considered in ([@gkr621-B20]), hence advancing the state of the art on this important topic.

Our work makes three additional regulatory networks---central nervous system, imaginal disc and ventral ectoderm---amenable to supervised CRM prediction. Our experiments also contribute 10 new CRMs, involved in development of early mesoderm and of somatic muscle, to the literature.

Our new method, along with our previously compiled techniques ([@gkr621-B20]), represents a flexible, accurate way of identifying regulatory sequences, especially for less fully described processes for which we lack the knowledge of relevant transcription factors. It can prove to be an important *in silico* adjunct to and extension of empirical CRM discovery approaches. Furthermore, it has the potential to lead to novel CRM predictions in experimentally less well-characterized arthropods such as mosquito, wasp, beetle and honeybee, while exploiting existing collections of CRMs in *Drosophila*.

We have also made a key improvement to the evaluation methodology for genome-wide CRM prediction methods, by proposing the locus LLHT. This new test is shown to lead to superior specificity (lower false positive rate) when enrichment tests are performed with gene sets of unusually large locus lengths. The Hypergeometric test of significance of overlap between gene sets forms the basis of many tools used in genomics, and the common phenomenon of locus length variability therefore casts doubts on the statistical inferences from these tools ([@gkr621-B26]). Our modification to the Hypergeometric test (LLHT) thus has the potential of widespread usability in contexts beyond CRM discovery.

SUPPLEMENTARY DATA
==================

[Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gkr621/DC1) are available at NAR Online.
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[^1]: The second and third columns show the total number of genes in the expression data source and the size of expression gene set for each data set, respectively (the size of the predicted gene set is 200 for all data sets). The lowest (best) *P-*value for each pair is shaded. Note that the *P-*values reported here are LLHT *P-*values, which are different from the standard Hypergeometric *P-*values shown in [Table 2](#gkr621-T2){ref-type="table"} of ([@gkr621-B20]).

[^2]: The second and third columns show the number of training CRMs and the size of expression gene set, respectively, for each data set. Scores of genes in an expression gene set were compared to scores of a collection of randomly chosen genomic regions. The score of a sequence is the maximum score in that region, under a CRM prediction scheme. For each gene in the expression gene set, 50 random genomic segments of length equal to the gene\'s territory length were included in the random collection. The last seven columns show the *P-*values (Wilcoxon rank sum test) of such a comparison for each data set and for each method. The best *P-*value for each data set is shaded. The last row indicates the number of times that a method is superior (smallest *P-*value).
